Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive formation of renal cysts which ultimately lead to a loss of renal function. Tolvaptan (a V2R antagonist) is currently the only effective treatment for preserving renal function in ADPKD. However, side-effects such as polyuria limit its tolerability and thereby the therapeutic potential. This study will test whether co-administration with hydochlorothiazide can improve V2RA efficacy (slowing kidney function decline) and tolerability (quality of life) in ADPKD. Approximately 300 patients will be enrolled.
Aims: The main objectives of the current study are to prospectively test whether HCT co-treatment can improve V2RA efficacy (slowing kidney function decline) and tolerability (quality of life) in PKD. Study design: Investigator driven randomized placebo-controlled multicenter trial Study population: 300 ADPKD patients of ≥18 years, with an eGFR of \> 25 mL/min/1.73m2, on stable treatment with the highest tolerated dose of V2RA Intervention: Oral HCT 25 mg once daily or matching placebo for a total of 156 weeks. The randomization ratio will be 1:1. Study visit schedule: study measurements will be performed during 12-weekly visits (which is routine care for V2RA treated patients), except for one additional study visit (or telephone call) 2 weeks after the start of treatment Primary study outcome: Slope of kidney function decline (measured by eGFR)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
300
An oral capsule containing 25mg of hydrochlorothiazide
A matching oral capsule containing placebo
Uniklinikum Graz
Graz, Austria
RECRUITINGMedizinische Universität Innsbruck
Innsbruck, Austria
RECRUITINGUniversitair Ziekenhuis Antwerpen (UZA)
Antwerp, Belgium
RECRUITINGCliniques Universitaires Saint-Luc
Brussels, Belgium
RECRUITINGUniversity Hospital Leuven
Leuven, Belgium
RECRUITINGHôpital Pellegrin (CHU Bordeaux)
Bordeaux, France
RECRUITINGHospital La Cavale Blanche
Brest, France
RECRUITINGCentre Hôpital Universitaire de Lyon
Lyon, France
RECRUITINGHôpitaux de Brabois (CHRU)
Nancy, France
RECRUITINGNecker-Enfants Malades Hospital
Paris, France
RECRUITING...and 15 more locations
Changes in kidney function decline
The primary outcome is the change in kidney function decline (assessed as eGFR slope, in ml/min/1.73 m2 per year), calculated with linear mixed models, using all available creatinine values from week 12 until end of treatment between the tolvaptan/placebo and tolvaptan/HCT group.
Time frame: 156 weeks
Changes in eGFR from baseline compared to end of study (12 weeks after End of Treatment)
A secondary outcome is the change in eGFR from baseline compared to end of study (12 weeks after end of treatment)
Time frame: 168 weeks
Incidence of 30% decrease in eGFR, end stage kidney disease (EKSD) or renal death
A secondary outcome is the incidence of a 30% decrease in eGFR, occurrence of end stage kidney disease (EKSD) or renal death during the entire study period (until the end of study (12 weeks after end of treatment)
Time frame: 168 weeks
Changes in 24-hour urine volume
A secondary outcome is the change in 24-hour urine volume, measured at baseline, week 12, week 48, week 96 and week 156 (end of treatment)
Time frame: 156 weeks
Quality of life, assessed by the TIPS questionnaire
Changes in Quality of Life measured by the Tolvaptan Impact of Polyuria Scale questionnaire (TIPS) at baseline, week 12, week 48, week 96 and week 156 (end of treatment)
Time frame: 156 weeks
Quality of life, assessed by the ADPKD-UIS questionnaire
Changes in Quality of Life measured by the ADPKD-Urinary Impact Scale questionnaire (ADPKD-UIS) at baseline, week 12, week 48, week 96 and week 156 (end of treatment)
Time frame: 156 weeks
Quality of life, assessed by the SF-12 questionnaire
Changes in Quality of Life measured by the Short Form 12 questionnaire (SF-12) at baseline, week 12, week 48, week 96 and week 156 (end of treatment)
Time frame: 156 weeks
Quality of life, assessed by the EQ-5D questionnaire
Changes in Quality of Life measured by the EuroQol-5 Dimension questionnaire (EQ-5D) at baseline, week 12, week 48, week 96 and week 156 (end of treatment)
Time frame: 156 weeks
Change in V2RA dose
V2RA dose during each study visit and compared at the end of study visit (12 weeks after end of treatment) between tolvaptan/placebo and tolvaptan/hydrochlorothiazide group
Time frame: 168 weeks
Change in V2RA discontinuation rate
The V2RA discontinuation rate will be compared at the end of study visit (12 weeks after end of treatment) between tolvaptan/placebo and tolvaptan/hydrochlorothiazide group
Time frame: 168 weeks
Changes in serum sodium concentration
Changes in serum sodium concentration between tolvaptan/placebo and tolvaptan/hydrochlorothiazide group, measured from baseline until the end of study (12 weeks after end of treatment)
Time frame: 168 weeks
Changes in serum potassium concentration
Changes in serum potassium concentration between tolvaptan/placebo and tolvaptan/hydrochlorothiazide group, measured from baseline until the end of study (12 weeks after end of treatment)
Time frame: 168 weeks
Changes in plasma serum calcium concentration
Changes in plasma serum calcium concentration between tolvaptan/placebo and tolvaptan/hydrochlorothiazide group, measured from baseline until the end of study (12 weeks after end of treatment)
Time frame: 168 weeks
Changes in serum phosphate concentration
Changes in serum phosphate concentration between tolvaptan/placebo and tolvaptan/hydrochlorothiazide group, measured from baseline until the end of study (12 weeks after end of treatment)
Time frame: 168 weeks
Incidence of (serious) adverse events
Incidence of (serious) adverse events from baseline until the end of study (12 weeks after end of treatment)
Time frame: 168 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.